JACOB GORDON: Open Payments
NPI 1417568049 · WASHINGTON, DC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$708 in 27 payments from 10 companies in 2025. Trend: 2023 $0 · 2024 $0 · 2025 $708
Food & beverage: $708
| Company | Payments | Amount |
|---|---|---|
| United Therapeutics Corporation | 7 | $256 |
| Bayer Healthcare Pharmaceuticals Inc. | 4 | $101 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 5 | $97 |
| Actelion Pharmaceuticals US, Inc. | 3 | $76 |
| Melinta Therapeutics, LLC | 2 | $33 |
| Astellas Pharma US Inc | 1 | $32 |
| Invivyd Inc | 2 | $31 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $30 |
| ABBVIE INC. | 1 | $26 |
| Insmed, Inc. | 1 | $25 |
Products named: Adempas, Orenitram, JASCAYD, UPTRAVI, OFEV, Tyvaso, Rezzayo, Cresemba.
Industry payments across DC — which companies pay providers there.
